论文部分内容阅读
使用深圳海滨制药有限公司研制的海舒必（舒巴坦／头孢哌酮钠（１∶１））与进口舒普深随机对照观察治疗１２８例下呼吸道和尿路感染，结果显示：海舒必和舒普深在治疗细菌感染的疗效和安全性方面无显著性差异。
128 cases of lower respiratory tract and urinary tract infection were treated with SHSB (sulbactam / cefoperazone sodium (1: 1)) which was developed by Shenzhen Haibin Pharmaceutical Co., Ltd. and a deep control of imported shuopu. The results showed that: Deep in the treatment of bacterial infections efficacy and safety no significant difference.